Drug class
Diagnostic radiopharmaceutical; positron-emission tomography (PET) dopaminergic imaging agent
Mechanism of action
Fluorodopa F 18 enters dopaminergic nerve terminals via amino-acid transport and is decarboxylated by aromatic L-amino-acid decarboxylase to fluorodopamine F 18, which is retained in presynaptic vesicles. Striatal accumulation is visualised by PET.
General use cases
- PET imaging of striatal dopaminergic nerve terminals as an adjunct in the evaluation of adults with suspected parkinsonian syndromes.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
